Phase III study of D9421-C 9 mg in patients with active Crohn's Disease in Japan

Exclusion Criteria

• - Patient with CD lesion or status which may affect the evaluation of the efficacy (e.g. lesion only in the upper G-I, active anorectal lesion, abscess formation, stenosis, fistulae, ostomy, short bowel or other uncontrolled concomitant disease)
• - Patient who need any concomitant treatment for CD that may affect the assessment for efficacy of the study drug
• - Patient who need any medication which is prohibited due to suspected influence to metabolism of the study drug
• - Patient who is judged to be inadequate to participate in this study from the safety point of view Patient with well-founded doubt about protocol violation